Expression of CD20 in B cell precursor acute lymphoblastic leukemia

Indian Journal of Hematology and Blood Transfusion

Volumn 30, Issue 1, 2014, Pages 16-18

  Kumar, Jeevan ^a   Khan, Afaq Ahmad ^a   Saraf, Amrita ^a   Bhargava, Manorama ^a  

^a SIR GANGA RAM HOSPITAL   (India)

Author keywords

BCP ALL; CD20 antigen; Rituximab

Indexed keywords

CD20 ANTIGEN; RITUXIMAB;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ANTIGEN DETECTION; ANTIGEN EXPRESSION; ARTICLE; CHILD; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG POTENCY; FEMALE; HEPATOMEGALY; HUMAN; INDIA; INFANT; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PRE B LYMPHOCYTE; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; SPLENOMEGALY;

EID: 84896736144     PISSN: 09714502     EISSN: 09740449     Source Type: Journal    
DOI: 10.1007/s12288-012-0216-1     Document Type: Article

References (9)

1. Jeha S, Behm F, Pei D et al (2006) Prognostic significance of CD20 expression in childhood B-cell precursor acute lymphoblastic leukemia. Blood 108:3302-3304
2. Borowitz MJ, Shuster J, Carroll AJ et al (1997) Prognostic significance of fluorescence intensity of surface marker expression in childhood B-precursor acute lymphoblastic leukemia: a Pediatric Oncology Group Study. Blood 89:3960-3966
3. Gökbuget N, Hoelzer D (2004) Treatment with monoclonal antibodies in acute lymphoblastic leukemia: current knowledge and future prospects. Ann Hematol 83(4):201-205
4. Dworzak MN, Schumich A, Printz D et al (2008) CD20 up-regulation in pediatric B-cell precursor acute lymphoblastic leukemia during induction treatment: setting the stage for anti-CD20 directed immunotherapy. Blood 112:3982-3988
5. Maury S, Huguet F, Leguay T, Lacombe F, Maynadié M, Girard S, de Labarthe A, Kuhlein E, Raffoux E, Thomas X, Chevallier P, Buzyn A, Delannoy A, Chalandon Y, Vernant J-P, Rousselot P, Macintyre E, Ifrah N, Dombret H, Béné MC, Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL) (2010) Adverse prognostic significance of CD20 expression in adults with Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia. Haematologica 95:324-328
6. Harris M (2004) Monoclonal antibodies as therapeutic agents for cancer. Lancet Oncol 5:292-302
7. Thomas DA, Faderl S, O'Brien S, Bueso-Ramos C, Cortes J, Garcia-Manero G et al (2006) Chemoimmunotherapy with hyper-CVAD plus Rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. Cancer 106(7):1569-1580
8. Claviez A, Eckert C, Seeger K et al (2006) Rituximab plus chemotherapy in children with relapsed or refractory CD20 B-cell precursor acute lymphoblastic leukemia. Haematologica 91:272-273
9. Morris ES, Vora A (2007) Remission induction with single agent Rituximab in a child with multiply relapsed precursor-B ALL. Br J Haemotol 139:344-345